All details for Anthem Biosciences IPO: Dates, price, subscription, financials, objectives, KPIs, registrar, and company overview.
Price Band: ₹540–570 | Allotment July 17 | Listing July 21, 2025
Anthem Biosciences IPO: At a Glance
IPO Timeline
| IPO Activity | Date |
|---|---|
| IPO Open Date | July 14, 2025 |
| IPO Close Date | July 16, 2025 |
| Tentative Allotment | July 17, 2025 |
| Refunds Initiation | July 18, 2025 |
| Credit of Shares to Demat | July 18, 2025 |
| IPO Listing Date | July 21, 2025 |
Anchor Investors
| Bid Date | Shares Offered | Anchor Portion Size (₹ Cr) | Lock-in (50%) | Lock-in (90%) |
|---|---|---|---|---|
| July 11, 2025 | 1,78,24,999 | 1,016.02 | Aug 16, 2025 | Oct 15, 2025 |
IPO Price & Lot Size
| Price Band | ₹540–570 per share |
|---|---|
| Market Lot | 26 Shares |
| Retail Min | 1 lot (26 shares) – ₹14,820 |
| Retail Max | 13 lots (338 shares) – ₹1,92,660 |
| S-HNI Min | 14 lots (364 shares) – ₹2,07,480 |
| S-HNI Max | 67 lots (1,742 shares) – ₹9,92,940 |
| B-HNI Min | 68 lots (1,768 shares) – ₹10,07,760 |
Company Financials (₹ Crore)
Bar Chart: Revenue, PAT & Net Worth
Line Chart: Revenue, PAT & Net Worth
| Period Ended | Assets | Revenue | Profit After Tax | EBITDA | Net Worth | Reserves & Surplus | Total Borrowing |
|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 2,807.58 | 1,930.29 | 451.26 | 683.78 | 2,409.86 | 2,298.05 | 108.95 |
| 31 Mar 2024 | 2,398.11 | 1,483.07 | 367.31 | 519.96 | 1,924.66 | 1,815.39 | 232.53 |
| 31 Mar 2023 | 2,014.46 | 1,133.99 | 385.19 | 446.05 | 1,740.67 | 1,628.88 | 125.06 |
Key Performance Indicators (KPI)
| KPI | Values |
|---|---|
| Market Cap | ₹31,867.39 Cr |
| ROE | 20.82% |
| ROCE | 26.88% |
| Debt/Equity | 0.05 |
| RoNW | 20.82% |
| PAT Margin | 23.38% |
| EBITDA Margin | 36.81% |
| Price to Book Value | 13.23 |
| EPS (Pre IPO) | 8.07 |
| EPS (Post IPO) | 8.07 |
| P/E (Pre IPO) | 70.62 |
| P/E (Post IPO) | 70.62 |
Objects of the Issue
| S.No. | Objects | Expected Amount |
|---|---|---|
| 1 | All offer proceeds go to Selling Shareholders (no proceeds to company) | — |
About Anthem Biosciences Ltd.
Incorporated: 2006
Business: Innovation-driven, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO); fully integrated drug discovery, development, and manufacturing.
Products: Specialized fermentation-based APIs (probiotics, enzymes, peptides, nutritional actives, vitamin analogues, biosimilars).
Clients: 150+ customers (as of Mar 2024); 425+ (CRDMO/specialty ingredients, Sep 2024); 44 countries incl. US, Europe, Japan.
Projects: 196 (Sep 2024): 170 discovery, 132 early phase, 16 late phase, 13 commercial manufacturing.
Patents: 1 India, 7 overseas, 24 pending global apps (Sep 2024).
Employees: 600+ (Sep 2024): chemists, microbiologists, molecular biologists, biochemists, chemical engineers.
Promoters: Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, Ishaan Bhardwaj
Strengths:
- One-stop service across drug lifecycle (small molecules, biologics)
- Innovation and technology focused
- Diversified customer base and long relationships
- Professional leadership & talent pool
Contact Details
No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1,
Bommasandra, Bengaluru, Karnataka, 560099
Phone: +91 080 6672 400
Email: investors.abl@anthembio.com
Website: https://www.anthembio.com/
Frequently Asked Questions (FAQ)
The price band for Anthem Biosciences IPO is ₹540–₹570 per share, as announced in the Draft Red Herring Prospectus (DRHP).
The IPO will open for subscription on July 14, 2025, and close on July 16, 2025, as per the announced timeline.
The minimum investment for retail investors is 1 lot (26 shares), which amounts to ₹14,820 at the upper end of the price band (₹570 per share). Employees are eligible for a ₹50 per share discount.
You can apply for the IPO through:
- Your bank's net banking platform (ASBA facility)
- Brokerage accounts (online or offline)
- Registered investment platforms
- Designated branches of syndicate banks
The exact application process will be detailed in the Red Herring Prospectus (RHP) when the IPO dates are confirmed. Note that bidding at the cut-off price is not allowed for sNII/bNII categories.
Anthem Biosciences Ltd. is an innovation-driven, technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO). Its revenue sources include:
- Drug discovery, development, and manufacturing services for small molecules and biologics
- Specialized fermentation-based APIs (probiotics, enzymes, peptides, nutritional actives, vitamin analogues, biosimilars)
- Serving 425+ customers across 44 countries, including the US, Europe, and Japan
- Projects spanning discovery (170), early phase (132), late phase (16), and commercial manufacturing (13) as of September 2024
The company’s one-stop service model and diversified customer base drive its revenue growth.
Key risks to consider include:
- Market risk: Dependence on global pharmaceutical and biotech demand, sensitive to economic and regulatory changes
- Operational risk: Reliance on complex R&D and manufacturing processes
- Competition: Intense competition from other CRDMOs globally
- Regulatory risk: Compliance with stringent regulations in multiple jurisdictions
- Financial risk: High P/E ratio (70.62) indicating potential valuation concerns
Investors should review the risk factors in the RHP before investing.
The IPO is an Offer for Sale (OFS) of 5,95,61,404 shares, and all proceeds (₹3,395 Cr at the upper price band) will go to the selling shareholders. The company will not receive any proceeds from the IPO.
Anthem Biosciences has:
- Revenue growth from ₹1,133.99 Cr (FY23) to ₹1,930.29 Cr (FY25)
- PAT growth from ₹385.19 Cr (FY23) to ₹451.26 Cr (FY25)
- Net worth growth from ₹1,740.67 Cr (FY23) to ₹2,409.86 Cr (FY25)
- EBITDA growth from ₹446.05 Cr (FY23) to ₹683.78 Cr (FY25)
- 600+ employees, including chemists, microbiologists, and engineers, as of September 2024
- 196 projects and 425+ customers across 44 countries as of September 2024
- 1 Indian patent, 7 overseas patents, and 24 pending global applications
The company’s innovation-driven model and global reach drive its financial and operational growth.
As of March 31, 2025:
- Total borrowings: ₹108.95 crore
- Debt-to-equity ratio: 0.05
- EBITDA: ₹683.78 Cr, supporting strong debt servicing capacity
The company maintains a low debt-to-equity ratio, reflecting a strong financial position.
The book running lead managers for Anthem Biosciences IPO are not specified in the provided data. They will be announced in the RHP and are responsible for managing the IPO process, including investor roadshows, price discovery, and allocation.
